NCT04063527招募中3 期
Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 360
- 试验地点
- 103
- 主要终点
- Overall survival
研究概览
简要总结
To compare the Overall survival of adjuvant chemotherapy versus observation in stage I epithelial ovarian cancer after comprehensive staging surgery
详细描述
Based on the following adjustment factors, patients will be randomly assigned in a 1:1 ratio to adjuvant chemotherapy or observation groups.
- Histologic type: clear cell adenocarcinoma/mucinous adenocarcinoma vs. serous adenocarcinoma/other histologic types
- Facility where a subject is enrolled
- International Federation of Gynecology and Obstetrics(FIGO) clinical staging: Stage Ia/ Ib vs. Stage Ic(b)
Group A: adjuvant chemotherapy group (standard treatment group):
While one of the following treatments will be performed, the number of cycles is entrusted to the treatment policy of each facility.
Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles Docetaxel plus Carboplatin (DC) therapy; Docetaxel(DTX) 70 mg/m2 + CBDCA AUC 6 q3weeks day1, 3 to 6 cycles
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of histopathologically epithelial ovarian cancer
- •FIGO Stages Ia(Grade2/3, clear cell carcinoma), Ib(Grade2/3, clear cell carcinoma) and Ic(b)(all degree of differentiation and all histologic type)
- •Patients with a diagnosis of advanced stage by comprehensive staging or restaging laparotomy.
- •Patients who received comprehensive staging surgery (basic surgical techniques (total hysterectomy, bilateral salpingo-oophorectomy, and omentectomy) as well as peritoneal cytology, multiple biopsies of the peritoneum ([Peritoneal biopsy] see details below), retroperitoneal lymph node dissection (see details below [Retroperitoneal lymph node dissection]).
- •However, for the following cases, it is eligible as a condition to record on the official document.
- •Peritoneal biopsy: peritoneal metastasis is not recognized by macroscopic and palpation in the stipulated site, and the case that biopsy has not been performed.
- •Retroperitoneal lymph node dissection: the case that lymph nodes of the stipulated range has been dissected however the prescribed number has not been reached.
- •Age: 20 or older
- •Performance status (PS):0-1
- •Case with initial therapy for postoperative primary lesion
- •Patient possible to receive the first study treatment within 8 weeks after the comprehensive staging surgery
- •Reasonable organ function
- •Patient must have signed informed consent.
排除标准
- •FIGO Stages Ic(a), Ic(1) and Ic(2)
- •Patients containing sarcoma elements
- •Patients with any signs of interstitial pneumonia or pulmonary fibrosis by chest radiography and CT
- •Patients with serious complications
- •Patients with active infection
- •Patients with intestinal paralysis or intestinal obstruction
- •Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy
- •Patients with previous chemotherapy or radiation therapy
- •Patients with serious drug hypersensitivity
- •Patients with peripheral motor/sensory neuropathy [grade2,3,4 Common Terminology Criteria for Adverse Events (CTCAE) 4.0]
- •Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
- •Patients with positive HBsAg. Patients with more than 2.1 log/copies ml based on fixed Hepatitis B virus (HBV)-DNA who are positive with either antigen-positive Hepatitis B (HBs), anti-hepatitis B core antigen or anti-hepatitis B surface antigen.
- •Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician
研究组 & 干预措施
Standard therapy
Active Comparator
combination of paclitaxel and carboplatin
干预措施: adjuvant chemotherapy (Drug)
结局指标
主要结局
Overall survival
时间窗: From date of randomization until the date of death from any cause, assessed up to 60 months
1. In surviving patients, cut off will be on the last date the patient is confirmed to be alive. 2. If a patient is lost to follow-up, cut off will be on the last date the patient is confirmed to be alive before being lost to follow-up.
次要结局
- Relapse-free survival(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months)
研究者
研究点 (103)
Loading locations...
相似试验
已完成
3 期
Immunotherapy Study for Surgically Resected Pancreatic CancerPancreatic CancerNCT01072981NewLink Genetics Corporation722
已完成
3 期
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder UrotheliumStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderNCT00028756European Organisation for Research and Treatment of Cancer - EORTC285
招募中
3 期
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPHGastric Cancer, Adjuvant Chemotherapy, XONCT01935778Asan Medical Center286
进行中（未招募）
3 期
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic CancerPancreatic Adenosquamous CarcinomaResectable Pancreatic AdenocarcinomaPancreatic CancerStage I Pancreatic Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8NCT04340141Alliance for Clinical Trials in Oncology358
暂停
不适用
A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low risk for recurrencenon-small-cell lung cancerNL-OMON27925VALT oncology864